uniQure (NASDAQ:QURE) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen cut shares of uniQure (NASDAQ:QURE - Free Report) from a hold rating to a sell rating in a report published on Saturday morning.

Several other brokerages have also recently issued reports on QURE. Wells Fargo & Company cut their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Guggenheim restated a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Chardan Capital restated a "buy" rating and issued a $38.00 target price on shares of uniQure in a report on Friday, May 30th. Finally, Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.82.

uniQure Price Performance

NASDAQ QURE traded down $0.32 on Friday, reaching $14.79. 1,968,812 shares of the company's stock traded hands, compared to its average volume of 1,930,850. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99. The stock has a 50-day simple moving average of $13.84 and a 200 day simple moving average of $13.72. The stock has a market cap of $810.20 million, a PE ratio of -3.37 and a beta of 0.08.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. The business had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million. As a group, research analysts predict that uniQure will post -3.75 earnings per share for the current year.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its stake in uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after acquiring an additional 502,684 shares during the period. Oppenheimer & Co. Inc. purchased a new position in uniQure during the fourth quarter valued at $320,000. Palumbo Wealth Management LLC purchased a new position in uniQure during the fourth quarter valued at $437,000. Raymond James Financial Inc. purchased a new position in uniQure during the fourth quarter valued at $1,951,000. Finally, Assenagon Asset Management S.A. lifted its position in uniQure by 355.2% during the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock valued at $3,550,000 after buying an additional 261,323 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.